In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pliva/Indevus: Moving Up the Value Chain

Executive Summary

Pliva's not the obvious choice of US marketing partner for Indevus' overactive bladder drug Sanctura. With no primary care presence in the US, the company will likely face an uphill battle to commercialize the drug; more so given the stiff competition in OAB from some of the world's leading Big Pharma marketeers. Yet the deal's about more than success with Sanctura. It's about both parties moving up the value chain--Pliva into the US proprietary drugs arena and Indevus into sales and marketing.
Advertisement

Related Content

Pliva: Two Steps Forward, One Step Back?
Pliva: Two Steps Forward, One Step Back?
Endo: Accessing Primary Care through Specialist Marketing
Endo: Accessing Primary Care through Specialist Marketing
Are Late-Stage Deals Beginning to Lose Their Luster?
Are Late-Stage Deals Beginning to Lose Their Luster?
Watson's Strategy for Beating the Big Boys
Watson's Strategy for Beating the Big Boys
Pliva: Europe is Not Enough

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002345

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel